ArticlePeerJ2026
Development and validation of a risk prediction model for overall survival in cervical cancer patients under 50: a prospective cohort study in southwest China.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of a prognostic prediction model incorporatingJournal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Accurately predicting the prognosis of cervical cancer in younger patients is increasingly important due to the rising incidence of the disease in China and the growing number of cases among individuals under 50. This study aimed to develop a nomogram to predict overall survival (OS) in cervical cancer patients under 50 in southwest China. Methods: Clinicopathological and follow-up data for cervical cancer patients under 50 were prospectively collected as part of an ongoing longitudinal cohort study at Chongqing University Cancer Hospital between January 1, 2015, and May 31, 2019. A training cohort ( Results: The final model identified pathology, International Federation of Gynecology and Obstetrics (FIGO) staging, treatment, β2-microglobulin, neutrophil-lymphocyte ratio (NLR), and albumin as independent risk factors for OS in patients under 50. The concordance index for OS was 0.818 in the training cohort and 0.747 in the validation cohort. Calibration curves in both cohorts showed strong agreement between predicted and observed survival probabilities. In the training cohort, AUCs for 1-, 3-, and 5-year OS were 0.851, 0.847, and 0.816, respectively; in the validation cohort, they were 0.810, 0.733, and 0.730. Compared to the FIGO staging system, the nomogram demonstrated superior predictive accuracy and net benefit, as shown by the net reclassification index (NRI) and DCA. Conclusion: The nomogram provides a reliable tool for predicting overall survival in cervical cancer patients under 50, supporting more personalized treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.